For patients with clinically significant autoimmune conditions, early comprehensive genomic profiling may help identify non-immunotherapy systemic options, such as PARP inhibition in the presence of BRCA2 or other HRD-associated alterations. Here, BRCA2 is linked to Autoimmunity.